Radius Health, Inc. (RDUS) Analysts See $-1.27 EPS; VOLTARI CORPORATION (VLTC) Sellers Decreased By 1.39% Their Shorts

Radius Health, Inc. (NASDAQ:RDUS) Logo

VOLTARI CORPORATION (OTCMKTS:VLTC) had a decrease of 1.39% in short interest. VLTC’s SI was 467,700 shares in February as released by FINRA. Its down 1.39% from 474,300 shares previously. With 3,300 avg volume, 142 days are for VOLTARI CORPORATION (OTCMKTS:VLTC)’s short sellers to cover VLTC’s short positions. The stock increased 2.02% or $0.0115 during the last trading session, reaching $0.5815. About 1,235 shares traded. Voltari Corporation (OTCMKTS:VLTC) has 0.00% since February 13, 2018 and is . It has by 0.00% the S&P500.

Analysts expect Radius Health, Inc. (NASDAQ:RDUS) to report $-1.27 EPS on March, 7.They anticipate $0.32 EPS change or 20.13% from last quarter’s $-1.59 EPS. After having $-1.09 EPS previously, Radius Health, Inc.’s analysts see 16.51% EPS growth. The stock decreased 1.99% or $0.39 during the last trading session, reaching $19.21. About 184,644 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has declined 41.81% since February 13, 2018 and is downtrending. It has underperformed by 41.81% the S&P500. Some Historical RDUS News: 08/03/2018 FBO:Veteran Aff: Veterans Affairs Contract Award – Q–Radius Health 02/15/2018 – 02/14/2023 – M5Q50A03R7; 21/04/2018 – DJ Radius Health Inc, Inst Holders, 1Q 2018 (RDUS); 30/03/2018 – Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis; 22/03/2018 – RADIUS HEALTH INC – EMA INFORMED CO THAT CHMP WILL ADOPT A NEGATIVE OPINION ON MAA ON THURSDAY; 22/03/2018 – Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC; 10/05/2018 – Radius Health 1Q Loss $61.6M; 13/04/2018 – RADIUS HEALTH CHIEF MEDICAL OFFICER FITZPATRICK TO STEP DOWN; 25/05/2018 – Radius Health Presenting at Goldman Sachs Conference Jun 12; 22/03/2018 – Radius Health: Intends to Appeal and Immediately Seek Re-Examination of CHMP Opinion; 11/04/2018 – Radius Health at Deutsche Bank Health Care Conference May 8

Among 2 analysts covering Radius Health (NASDAQ:RDUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Radius Health had 2 analyst reports since October 11, 2018 according to SRatingsIntel. The rating was maintained by JP Morgan on Friday, November 2 with “Overweight”. The company was maintained on Thursday, October 11 by Morgan Stanley.

Since August 14, 2018, it had 4 insider purchases, and 0 sales for $3.03 million activity. BIOTECH GROWTH N V bought 60,000 shares worth $868,782. 3,000 shares were bought by Kelly Joseph Francis, worth $47,130.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $874.81 million. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

Investors sentiment decreased to 1.4 in Q3 2018. Its down 0.32, from 1.72 in 2018Q2. It is negative, as 18 investors sold Radius Health, Inc. shares while 27 reduced holdings. 20 funds opened positions while 43 raised stakes. 47.19 million shares or 8.92% less from 51.82 million shares in 2018Q2 were reported. Amer Grp Incorporated Inc reported 26,847 shares stake. Td Asset Mngmt accumulated 58,300 shares or 0% of the stock. C A S holds 0% in Radius Health, Inc. (NASDAQ:RDUS) or 7,336 shares. Strs Ohio holds 200 shares or 0% of its portfolio. Ghost Tree Cap Lc invested 0.76% of its portfolio in Radius Health, Inc. (NASDAQ:RDUS). Blackrock Incorporated reported 3.30M shares. Farallon Ltd Limited Liability Company holds 0.21% or 2.04 million shares. Barclays Public Ltd holds 0% or 67,729 shares in its portfolio. Ontario – Canada-based Manufacturers Life Insur The has invested 0% in Radius Health, Inc. (NASDAQ:RDUS). Credit Suisse Ag invested 0% of its portfolio in Radius Health, Inc. (NASDAQ:RDUS). Daiwa Secs Group has invested 0% in Radius Health, Inc. (NASDAQ:RDUS). Dekabank Deutsche Girozentrale owns 189,400 shares. Morgan Stanley has invested 0% in Radius Health, Inc. (NASDAQ:RDUS). 80,476 were accumulated by Alps Advisors. Tudor Inv Et Al stated it has 97,932 shares.

More notable recent Radius Health, Inc. (NASDAQ:RDUS) news were published by: Nasdaq.com which released: “Radius Health Appoints Jessica Hopfield, Ph.D., to Board of Directors – Nasdaq” on January 25, 2019, also Investorplace.com with their article: “7 Oversold Small-Cap Stocks With Massive Profit Growth – Investorplace.com” published on January 16, 2019, Seekingalpha.com published: “Tesla: Promoted To A ‘Favorite’ Short – Seeking Alpha” on February 12, 2019. More interesting news about Radius Health, Inc. (NASDAQ:RDUS) were released by: Nasdaq.com and their article: “Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up – Nasdaq” published on August 07, 2018 as well as Nasdaq.com‘s news article titled: “Why Is Radius Health (RDUS) Down 9.7% Since its Last Earnings Report? – Nasdaq” with publication date: June 11, 2018.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Chart